US CNS Executive Order

AI SummaryClose X

Solvonis Therapeutics plc welcomes President Trump's Executive Order on accelerating medical treatments for serious mental illness, viewing it as a positive signal for rapid-acting CNS and psychedelic-adjacent therapies, particularly in the U.S. market. While not directly related to specific company programs, the order is highly relevant to Solvonis' pipeline, which includes SVN-001 for severe alcohol use disorder, SVN-002 for moderate-to-severe alcohol use disorder in the U.S., SVN-015 for stimulant addiction, and SVN-114 for PTSD. The company believes this U.S. policy shift supports its long-term positioning and the attractiveness of the U.S. as a commercial, regulatory, and capital-markets environment for innovative CNS therapeutics.

Disclaimer*

UK 100

Latest directors dealings